moderna inc. - MRNA

MRNA

Close Chg Chg %
51.28 0.06 0.12%

Pre-Market

51.34

+0.06 (0.12%)

Volume: 4.81M

Last Updated:

Mar 24, 2026, 4:00 PM EDT

Company Overview: moderna inc. - MRNA

MRNA Key Data

Open

$50.44

Day Range

50.34 - 52.68

52 Week Range

22.29 - 59.55

Market Cap

$20.25B

Shares Outstanding

394.94M

Public Float

361.21M

Beta

1.30

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$7.26

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

9.21M

 

MRNA Performance

1 Week
 
-0.08%
 
1 Month
 
-4.16%
 
3 Months
 
64.55%
 
1 Year
 
64.97%
 
5 Years
 
-61.48%
 

MRNA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 26
Full Ratings ➔

About moderna inc. - MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

MRNA At a Glance

Moderna, Inc.
325 Binney Street
Cambridge, Massachusetts 02142
Phone 1-617-714-6500 Revenue 1.94B
Industry Biotechnology Net Income -2,822,000,000.00
Sector Health Technology Employees 4,700
Fiscal Year-end 12 / 2026
View SEC Filings

MRNA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 5.901
Price to Book Ratio 1.343
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.44
Enterprise Value to Sales 3.589
Total Debt to Enterprise Value 0.187

MRNA Efficiency

Revenue/Employee 413,617.021
Income Per Employee -600,425.532
Receivables Turnover 6.845
Total Asset Turnover 0.147

MRNA Liquidity

Current Ratio 3.293
Quick Ratio 3.216
Cash Ratio 2.919

MRNA Profitability

Gross Margin 44.29
Operating Margin -158.128
Pretax Margin -142.387
Net Margin -145.165
Return on Assets -21.314
Return on Equity -28.868
Return on Total Capital -28.348
Return on Invested Capital -26.222

MRNA Capital Structure

Total Debt to Total Equity 15.087
Total Debt to Total Capital 13.109
Total Debt to Total Assets 10.577
Long-Term Debt to Equity 14.601
Long-Term Debt to Total Capital 12.687
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Moderna Inc. - MRNA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
19.11B 6.84B 3.24B 1.94B
Sales Growth
+3.78% -64.21% -52.69% -39.93%
Cost of Goods Sold (COGS) incl D&A
5.76B 5.31B 1.65B 1.08B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
348.00M 621.00M 189.00M 215.00M
Depreciation
348.00M 617.00M 185.00M 211.00M
Amortization of Intangibles
- 4.00M 4.00M 4.00M
COGS Growth
+102.32% -7.81% -68.89% -34.48%
Gross Income
13.35B 1.53B 1.58B 861.00M
Gross Income Growth
-14.26% -88.57% +3.74% -45.61%
Gross Profit Margin
+69.84% +22.31% +48.92% +44.29%
2022 2023 2024 2025 5-year trend
SG&A Expense
4.08B 5.77B 5.53B 3.94B
Research & Development
2.95B 4.22B 4.35B 2.92B
Other SG&A
1.13B 1.55B 1.17B 1.02B
SGA Growth
+75.37% +41.53% -4.24% -28.82%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
9.27B (4.25B) (3.94B) (3.07B)
Non Operating Income/Expense
338.00M 343.00M 362.00M 316.00M
Non-Operating Interest Income
200.00M 421.00M 425.00M 314.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
29.00M 38.00M 24.00M 10.00M
Interest Expense Growth
+61.11% +31.03% -36.84% -58.33%
Gross Interest Expense
29.00M 38.00M 24.00M 10.00M
Interest Capitalized
- - - -
-
Pretax Income
9.57B (3.94B) (3.61B) (2.77B)
Pretax Income Growth
-27.93% -141.17% +8.50% +23.26%
Pretax Margin
+50.11% -57.63% -111.46% -142.39%
Income Tax
1.21B 772.00M (46.00M) 54.00M
Income Tax - Current - Domestic
1.73B (153.00M) (58.00M) 15.00M
Income Tax - Current - Foreign
57.00M 24.00M 13.00M 29.00M
Income Tax - Deferred - Domestic
- - (576.00M) 896.00M
-
Income Tax - Deferred - Foreign
(2.00M) 5.00M (1.00M) 10.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
8.36B (4.71B) (3.56B) (2.82B)
Minority Interest Expense
- - - -
-
Net Income
8.36B (4.71B) (3.56B) (2.82B)
Net Income Growth
-31.47% -156.37% +24.46% +20.75%
Net Margin Growth
+43.76% -68.92% -110.04% -145.16%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
8.36B (4.71B) (3.56B) (2.82B)
Preferred Dividends
- - - -
-
Net Income Available to Common
8.36B (4.71B) (3.56B) (2.82B)
EPS (Basic)
21.2234 -12.3403 -9.2734 -7.2545
EPS (Basic) Growth
-29.90% -158.14% +24.85% +21.77%
Basic Shares Outstanding
394.00M 382.00M 384.00M 389.00M
EPS (Diluted)
20.101 -12.3403 -9.2734 -7.2545
EPS (Diluted) Growth
-29.00% -161.39% +24.85% +21.77%
Diluted Shares Outstanding
416.00M 382.00M 384.00M 389.00M
EBITDA
9.61B (3.63B) (3.76B) (2.86B)
EBITDA Growth
-28.63% -137.72% -3.59% +23.88%
EBITDA Margin
+50.31% -53.01% -116.07% -147.07%

Snapshot

Average Recommendation HOLD Average Target Price 41.842
Number of Ratings 26 Current Quarters Estimate -2.032
FY Report Date 03 / 2026 Current Year's Estimate -6.388
Last Quarter’s Earnings -2.11 Median PE on CY Estimate N/A
Year Ago Earnings -7.26 Next Fiscal Year Estimate -4.594
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 14 23 20
Mean Estimate -2.03 -2.08 -6.39 -4.59
High Estimates -1.65 -1.59 -3.80 -0.10
Low Estimate -2.81 -2.53 -7.80 -6.26
Coefficient of Variance -12.72 -12.10 -12.76 -26.89

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 4
OVERWEIGHT 0 0 1
HOLD 19 19 16
UNDERWEIGHT 2 2 3
SELL 2 2 2
MEAN Hold Hold Hold

Insider Actions for Moderna Inc. - MRNA

Date Name Shares Transaction Value
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Stephen Hoge President 1,457,763 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $51.71 per share 75,380,924.73
Mar 4, 2026 Stephen Hoge President 1,458,079 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 James M. Mock Chief Financial Officer 49,569 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Stéphane Bancel Chief Executive Officer; Director 250,932 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 41,658 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 38,553 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 29,275 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 25,992 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 6,189 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 1,315 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 54,760 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 59,689 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $52.29 per share 3,121,137.81
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 73,574 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $30.96 per share 2,277,851.04
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 59,689 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $51.71 per share 3,086,518.19
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 63,878 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 55,215 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $51.71 per share 2,855,167.65
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 55,590 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 54,816 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $51.71 per share 2,834,535.36
Mar 4, 2026 Shannon Thyme Klinger Chief Legal Officer 54,976 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Moderna Inc. in the News